Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imidazole SCHEMBL28896449 | 0.98 | ALDH1A1 (0.52) | ALDH1A1FKBP5CYP3A4TDP1KDM4E | |
| Biphenyl SCHEMBL986473 | 0.80 | ALDH1A1 (0.62) | ALDH1A1FKBP5CYP3A4KDM4ESLC6A2 | |
| Biphenyl SCHEMBL27756385 | 0.80 | ALDH1A1 (0.62) | ALDH1A1FKBP5CYP3A4KDM4ESLC6A2 | |
| Phenol SCHEMBL28247413 | 0.79 | ALDH1A1 (0.54) | ALDH1A1FKBP5SLC6A2SLC6A4SLC6A3 | |
| Phenol SCHEMBL19462651 | 0.79 | ALDH1A1 (0.54) | ALDH1A1FKBP5SLC6A2SLC6A4SLC6A3 | |
| Phenol SCHEMBL30286047 | 0.79 | ALDH1A1 (0.54) | ALDH1A1FKBP5SLC6A2SLC6A4SLC6A3 | |
| Benzene SCHEMBL18279961 | 0.79 | ALDH1A1 (0.87) | ALDH1A1FKBP5TDP1 | |
| Benzene SCHEMBL5088215 | 0.79 | ALDH1A1 (0.87) | ALDH1A1FKBP5TDP1 | |
| Benzene SCHEMBL29168770 | 0.79 | ALDH1A1 (0.87) | ALDH1A1FKBP5TDP1 | |
| Biphenyl SCHEMBL28667880 | 0.78 | ALDH1A1 (0.59) | ALDH1A1FKBP5CYP3A4KDM4ENOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148862-A1 | SKIN MICROENVIRONMENT TARGETED DELIVERY FOR PROMOTING IMMUNE AND OTHER RESPONSES | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-05-09 | — | — | US | disclosed |
| CN-113336717-B | Process for preparing oxazolecarboxylic acid esters | 江西天新药业股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| US-20230285731-A1 | MULTI-COMPONENT BIO-ACTIVE DRUG DELIVERY AND CONTROLLED RELEASE TO THE SKIN BY MICRONEEDLE ARRAY DEVICES | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-09-14 | — | — | US | disclosed |
| US-11744889-B2 | Skin microenvironment targeted delivery for promoting immune and other responses | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-09-05 | — | — | US | disclosed |
| US-11684763-B2 | Multi-component bio-active drug delivery and controlled release to the skin by microneedle array devices | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-06-27 | — | — | US | disclosed |
| US-11197873-B2 | Azolium salts for treatment of non-muscle invasive bladder cancer | THE UNIVERSITY OF AKRON (US) | 2021-12-14 | — | — | US | disclosed |
| CN-113336717-A | Process for preparing oxazole carboxylic acid esters | 江西天新药业股份有限公司 | 2021-09-03 | — | — | CN | disclosed |
| US-20200376009-A1 | AZOLIUM SALTS FOR TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER | THE INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | 2020-12-03 | — | — | US | disclosed |
| CN-109312156-A | Module is coped in hot curing resin composition, prepreg, plywood, printed wiring board and high-speed communication | 日立化成株式会社 | 2019-02-05 | — | — | CN | disclosed |
| US-20190000966-A1 | SKIN MICROENVIRONMENT TARGETED DELIVERY FOR PROMOTING IMMUNE AND OTHER RESPONSES | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-01-03 | — | — | US | disclosed |
| WO-2017120322-A1 | SKIN MICROENVIRONMENT TARGETED DELIVERY FOR PROMOTING IMMUNE AND OTHER RESPONSES | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-07-13 | — | — | WO | disclosed |
| WO-2017066768-A1 | MULLTI-COMPONENT BIIO-ACTIVE DRUG DELIVERY AND CONTROLLED RELEASE TO THE SKIN BY MICRONEEDLE ARRAY DEVICES | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-04-20 | — | — | WO | disclosed |
| US-8119692-B2 | Hydroxamic acid derivatives of 4-phenyl 4-hydroxy, 4-phenyl 4-alkoxy and 4-phenyl 4-arylalkoxy butyric acid useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA LLC (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100286125-A1 | Hydroxamic acid derivatives of 4-phenyl 4-hydroxy, 4-phenyl 4-alkoxy and 4-phenyl 4-arylalkoxy butyric acid useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA, LLC | 2010-11-11 | — | — | US | disclosed |
| WO-2009008920-A2 | HYDROXAMIC ACID DERIVATIVES OF 4-PHENYL 4-HYDROXY, 4-PHENYL 4-ALKOXY AND 4-PHENYL 4-ARYLALKOXY BUTYRIC ACID USEFUL AS THERAPEUTIC AGENTS FOR TREATING ANTHRAX POISONING | PANTHERA BIOPHARMA, LLC. (US) | 2009-01-15 | — | — | WO | disclosed |
| US-6372800-B1 | IMMUNOSUPPRESSIVE EFFECT AND IS USEFUL AS AN INHIBITOR FOR THE REJECTION REACTION OCCURRING IN ORGAN OR BONE MARROW TRANSPLANTATION, AND AS A PREVENTIVE OR REMEDY FOR ARTICULAR RHEUMATISM, ATOPIC ECZEMA (DERMATITIS), BEHCET'S DISEASE, | MITSUBISHI PHARMA CORPORATION (JP) | 2002-04-16 | — | — | US | disclosed |
| EP-0778263-B1 | BENZENE COMPOUND AND MEDICINAL USE THEREOF | WELFIDE CORP (JP) | 2002-01-09 | — | — | EP | disclosed |
| US-6187821-B1 | SUCH AS 2-AMINO-2-(3-(4-HEPTYLPHENYL)PROPYL)BUTANE-1,4-DIOL; IMMUNOSUPPRESSANT; ADMINISTERING TO TREAT OR PREVENT AUTOIMMUNE DISEASES AND ALLERGIES | WELFIDE CORPORATION (JP) | 2001-02-13 | — | — | US | disclosed |
| US-5948820-A | IMMUNOSUPPRESSANT; PREVENT REJECTION OF ORGAN TRANSPLANT;AUTOIMMUNE DISEASES; MULTIPLE SCLEROSIS; LUPUS; ANTIALLERGENS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0778263-A1 | BENZENE COMPOUND AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285731-A1 | MULTI-COMPONENT BIO-ACTIVE DRUG DELIVERY AND CONTROLLED RELEASE TO THE SKIN BY MICRONEEDLE ARRAY DEVICES | MMP17, FGF23, MMP1 | ALDH1A1 1560/4885FKBP5 529/4885CYP3A4 2082/4885 |
| US-11744889-B2 | Skin microenvironment targeted delivery for promoting immune and other responses | TSLP, CD69, CXCL12 | ALDH1A1 2984/4885FKBP5 419/4885CYP3A4 4795/4885 |
| US-20100286125-A1 | Hydroxamic acid derivatives of 4-phenyl 4-hydroxy, 4-phenyl 4-alkoxy and 4-phenyl 4-arylalkoxy butyric acid useful as therapeutic agents for treating anthrax poisoning | ANTXR2, ABAT, BAX | ALDH1A1 559/4885FKBP5 2584/4885CYP3A4 163/4885 |
| US-11197873-B2 | Azolium salts for treatment of non-muscle invasive bladder cancer | MYLK, CA5A, SLC14A1 | ALDH1A1 1030/4885FKBP5 615/4885CYP3A4 515/4885 |
| US-11684763-B2 | Multi-component bio-active drug delivery and controlled release to the skin by microneedle array devices | MMP17, FGF23, MMP1 | ALDH1A1 1560/4885FKBP5 529/4885CYP3A4 2082/4885 |
| US-20240148862-A1 | SKIN MICROENVIRONMENT TARGETED DELIVERY FOR PROMOTING IMMUNE AND OTHER RESPONSES | TSLP, CD69, CXCL12 | ALDH1A1 2984/4885FKBP5 419/4885CYP3A4 4795/4885 |
| US-20200376009-A1 | AZOLIUM SALTS FOR TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER | MYLK, CA5A, SLC14A1 | ALDH1A1 1030/4885FKBP5 615/4885CYP3A4 515/4885 |
| US-20190000966-A1 | SKIN MICROENVIRONMENT TARGETED DELIVERY FOR PROMOTING IMMUNE AND OTHER RESPONSES | TSLP, CD69, CXCL12 | ALDH1A1 2984/4885FKBP5 419/4885CYP3A4 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.